CSPC Pharma Secures US$10.00 million Milestone Payment from AstraZeneca under Small-Molecule R&D Pact

Bulletin Express08-05

CSPC Pharmaceutical Group Limited (CSPC Pharma) confirmed receipt of a US$10.00 million milestone payment from AstraZeneca on 5 August 2026. The payment follows AstraZeneca’s exercise of a license option for one of the pre-clinical candidate (PCC) programs covered by the strategic research collaboration signed on 13 June 2025.

Under the agreement, CSPC Pharma is responsible for discovering oral small-molecule PCCs targeting multiple disease areas, including immunological disorders. The latest milestone indicates that research and development activities are advancing as scheduled.

The collaboration grants AstraZeneca rights to develop, manufacture and commercialise licensed products arising from the selected PCCs. CSPC Pharma emphasised that future development, manufacturing and commercial outcomes remain subject to uncertainties and pledged to issue further announcements on any material developments.

Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities. The board of CSPC Pharma is chaired by Mr. Cai Dong Chen.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1173745599?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 18:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173745599","market":"us","top_or_hot":-1,"title":"CSPC Pharma Secures US$10.00 million Milestone Payment from AstraZeneca under Small-Molecule R&D Pact","media":"Bulletin Express","content":"<p>CSPC Pharmaceutical Group Limited (CSPC Pharma) confirmed receipt of a US$10.00 million milestone payment from AstraZeneca on 5 August 2026. The payment follows AstraZeneca’s exercise of a license option for one of the pre-clinical candidate (PCC) programs covered by the strategic research collaboration signed on 13 June 2025.</p>\n<p>Under the agreement, CSPC Pharma is responsible for discovering oral small-molecule PCCs targeting multiple disease areas, including immunological disorders. The latest milestone indicates that research and development activities are advancing as scheduled.</p>\n<p>The collaboration grants AstraZeneca rights to develop, manufacture and commercialise licensed products arising from the selected PCCs. CSPC Pharma emphasised that future development, manufacturing and commercial outcomes remain subject to uncertainties and pledged to issue further announcements on any material developments.</p>\n<p>Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities. The board of CSPC Pharma is chaired by Mr. Cai Dong Chen.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Pharma Secures US$10.00 million Milestone Payment from AstraZeneca under Small-Molecule R&D Pact</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Pharma Secures US$10.00 million Milestone Payment from AstraZeneca under Small-Molecule R&D Pact\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-05 18:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSPC Pharmaceutical Group Limited (CSPC Pharma) confirmed receipt of a US$10.00 million milestone payment from AstraZeneca on 5 August 2026. The payment follows AstraZeneca’s exercise of a license option for one of the pre-clinical candidate (PCC) programs covered by the strategic research collaboration signed on 13 June 2025.</p>\n<p>Under the agreement, CSPC Pharma is responsible for discovering oral small-molecule PCCs targeting multiple disease areas, including immunological disorders. The latest milestone indicates that research and development activities are advancing as scheduled.</p>\n<p>The collaboration grants AstraZeneca rights to develop, manufacture and commercialise licensed products arising from the selected PCCs. CSPC Pharma emphasised that future development, manufacturing and commercial outcomes remain subject to uncertainties and pledged to issue further announcements on any material developments.</p>\n<p>Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities. The board of CSPC Pharma is chaired by Mr. Cai Dong Chen.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1173745599","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173745599","pubTimestamp":1785924335,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CSPC Pharmaceutical Group Limited (CSPC Pharma) confirmed receipt of a US$10.00 million milestone payment from AstraZeneca on 5 August 2026. The payment follows AstraZeneca’s exercise of a license...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"石药集团根据小分子研发协议从阿斯利康获得 1000 万美元里程碑付款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"CSPC Pharmaceutical Group Limited (CSPC Pharma) confirmed receipt of a US$10.00 million milestone payment from AstraZeneca on 5 August 2026. The payment follows AstraZeneca’s exercise of a license option for one of the pre-clinical candidate (PCC) programs covered by the strategic research collaboration signed on 13 June 2025.\nUnder the agreement, CSPC Pharma is responsible for discovering oral small-molecule PCCs targeting multiple disease areas, including immunological disorders. The latest milestone indicates that research and development activities are advancing as scheduled.\nThe collaboration grants AstraZeneca rights to develop, manufacture and commercialise licensed products arising from the selected PCCs. CSPC Pharma emphasised that future development, manufacturing and commercial outcomes remain subject to uncertainties and pledged to issue further announcements on any material developments.\nShareholders and potential investors are advised to exercise caution when dealing in the company’s securities. The board of CSPC Pharma is chaired by Mr. Cai Dong Chen.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173745599","isCrawlerRequest":true}